Filing summary
Issuer/period: The supplied filing is Aquinox Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended December 31, 2016, filed March 9, 2017. It is not identified in the filing as a Neurogene Inc. filing, and it reports annual results rather than a standalone 2016 fourth quarter. Confirm the issuer and filing before relying on this summary.
Business context
Aquinox was a clinical-stage pharmaceutical company developing targeted therapies for inflammation and immuno-oncology. Its lead candidate, oral SHIP1 activator AQX-1125, was in Phase 3 development for interstitial cystitis/bladder pain syndrome (IC/BPS). The company had no approved products and had generated no revenue.
Financial results and position
| Metric (USD millions, except per-share data) | 2016 | 2015 |
|---|---|---|
| Revenue | 0 | 0 |
| Research and development expense | 28.4 | 15.8 |
| General and administrative expense | 9.3 | 5.5 |
| Total operating expenses | 37.6 | 21.3 |
| Net loss | 37.0 | 21.9 |
| Basic and diluted loss per share | $1.96 | $1.73 |
| Cash used in operating activities | 30.2 | 20.3 |
| Cash, cash equivalents and investments | 153.1 | 112.9 |
| Working capital | 94.0 | 70.0 |
| Total liabilities | 9.7 | 4.9 |
There was no product revenue, so operating margins are not meaningful. The $153.1 million 2016 liquidity figure includes cash, cash equivalents, short-term and long-term investments; the balance sheet separately reports $32.3 million cash and equivalents, $70.8 million short-term investments and $50.0 million long-term investments. The company reported no bank debt at year-end; remaining capital-lease obligations were $62,000 in present value. Accumulated deficit was $148.3 million.
Changes and notable items
- Net loss increased to $37.0 million from $21.9 million, while operating cash use rose to $30.2 million from $20.3 million.
- R&D expense rose 80%, mainly reflecting increased clinical activity as Leadership 301 began, plus a $2.3 million Biolipox milestone payment (CAD $3.0 million) following Phase 3 advancement.
- G&A expense increased, primarily due to personnel costs and establishing a San Bruno office.
- A September 2016 common-stock offering generated $70.7 million net proceeds. Shares outstanding increased from 17.2 million at year-end 2015 to 23.4 million at year-end 2016.
- Interest income rose to $0.6 million from $0.1 million, supported by higher cash and investment balances. No material interest expense was reported for 2016.
Outlook, risks and contingencies
- Leadership 301 enrolled patients beginning in the third quarter of 2016, testing 100 mg and 200 mg once-daily doses against placebo, with 12 weeks of dosing and a 40-week extension. Management expected top-line results in 2018 and anticipated a second Phase 3 trial thereafter; its design would be informed by Leadership 301 results.
- Management estimated existing capital would fund operations for at least 12 months from the filing’s reporting context, while also stating substantial future financing would likely be needed. Continued losses and cash burn were expected.
- Leadership 201’s primary pain endpoint did not achieve statistical significance (p=0.061), though several secondary endpoints favored AQX-1125 significantly. A separate COPD Phase 2 trial and an atopic dermatitis Phase 2 trial did not demonstrate efficacy. Leadership 301 had experienced site-initiation delays.
- Safety remains a development risk: gastrointestinal events were the most frequent clinical adverse events, and animal studies identified severe gastrointestinal ulcerations in dogs and ocular-lens effects. The filing cautions that animal findings may not predict human outcomes.
- Key exposures include an unvalidated SHIP1 target, Phase 3 execution and regulatory uncertainty, reliance on third-party research and manufacturing providers, future financing and dilution, reimbursement and commercialization risks, and patent protection. AQX-1125 patents were described as expiring in 2024 in Europe and 2024–2028 in the United States, subject to possible extensions.
- There were no material legal proceedings reported. The financial statements received an unqualified audit opinion; management concluded internal control over financial reporting was effective, while the auditor did not attest to that assessment under the emerging-growth-company exemption.
Investor verification priorities
- Verify that Aquinox Pharmaceuticals—not Neurogene Inc.—and the fiscal year ended December 31, 2016 are the intended issuer and period.
- Check subsequent Leadership 301 enrollment, results, timing and any change to the second-trial plan.
- Confirm cash runway using the full investment and cash-flow disclosures, and assess financing needs, dilution and spending trends.
- Review the significance of Leadership 201’s failed primary endpoint, prior indication-trial failures and disclosed animal toxicology findings.
- Verify patent scope and remaining term, manufacturing capacity and the status of clinical-site and regulatory dependencies.